Lupus (SLE) trials in United States

In United States 100 Also abroad 354

100 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
Where
Anniston, Clearwater, Greenacres City, Houston, Jackson, Kissimmee, Miami, Orland Park, Plantation, Red Oak, Tampa, Tustin
Age
18 years to 75 years
People
30 worldwide
Run by
AbbVie
See details and how to joinNCT07607964
Phase 1Taking people
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
Where
Anniston, Birmingham, Chapel Hill, Iowa City, La Jolla, Omaha, Sacramento
Age
18 years to 70 years
People
72 worldwide
Run by
AstraZeneca
See details and how to joinNCT06916806 · EU 2024-519015-34-00
No phaseTaking people
Lupus Nephritis Care Pathway
Where
Durham
Age
18 years and over
People
25
Run by
Duke University
See details and how to joinNCT07783152
Phase 3Enrolling by invitation
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
Where
Atlanta, Avondale, Beckley, Bellaire, Beverly Hills, Birmingham, Brandon, Canton, Charlotte, Chicago, Colleyville, Denver, Detroit, Gainesville, Glendale, Hagerstown, Hershey, Hopkinsville, Idaho Falls, Jackson, Lake Charles, La Palma, Las Vegas, Manhasset, Miami, New Orleans, New York, Ormond Beach, Phoenix, Plantation, San Leandro, Tampa, Tucson
Age
16 years and over
People
760 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT04976322 · EU 2023-506368-14-00
Phase 1Not yet taking people in United States
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
Where
Ann Arbor, Great Neck, Morristown, Newport Beach, Omaha, Philadelphia, Saint Paul, Salt Lake City, Seattle, Worcester
Age
18 years and over
People
60 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07873931
No phaseNot yet taking people in United States
Home-Based High-Intensity Interval Training in Systemic Lupus Erythematosus
Where
Birmingham
Age
18 years to 65 years
People
20
Run by
University of Alabama at Birmingham
See details and how to joinNCT07716462
Phase 1/2Taking people
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Where
Atlanta, Boston, Chapel Hill, Charleston, Chicago, Gainesville, Houston, Jacksonville, Kansas City, Minneapolis, New Haven, New York, Orange, Philadelphia, Rochester, Sacramento, Worcester
Age
12 years to 65 years
People
28 worldwide
Run by
Cabaletta Bio
See details and how to joinNCT06121297 · EU 2023-507613-10-01
Phase 1Taking people
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Where
Atlanta, Baltimore, Bethesda, Birmingham, Boston, Chicago, City of Saint Peters, Columbus, Creve Coeur, Dallas, Detroit, Fairway, Fort Worth, Hays, Houston, Kansas City, Lawrence, Lee's Summit, Lexington, Mineola, New Brunswick, New Haven, New York, North Kansas City, Olathe, Overland Park, Palo Alto, Philadelphia, Pittsburg, Pittsburgh, Richardson, Richmond, Sacramento, Salina, Salt Lake City, St Louis, Topeka, Washington D.C., Westwood
Age
18 years and over
People
300 worldwide
Run by
National Cancer Institute (NCI)
See details and how to joinNCT03816345
Phase 3Enrolling by invitation
A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)
Where
Allen, Aurora, Austin, Aventura, Avon Park, Baytown, Beverly Hills, Brooklyn, Charlotte, Cincinnati, Clearwater, Colleyville, Cooper City, DeBary, Flint, Gainesville, Houston, Humble, Huntington Beach, Jackson, Katy, Margate, Memphis, Middleburg Heights, Mission Hills, Orlando, Phoenix, Rochester Hills, Salisbury, San Antonio, Seattle, St Louis, Tampa, The Woodlands, Upland, Washington D.C., Worcester
Age
18 years and over
People
864 worldwide
Run by
Biogen
See details and how to joinNCT05352919 · EU 2023-505635-13-00
Phase 2Taking people
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
Where
Aurora, Boston, Cleveland, Great Neck, Hawthorne, Hialeah, Homestead, Houston, Miami, New Orleans, New York, Rochester, Scottsdale, Seattle, South Miami
Age
18 years to 75 years
People
220 worldwide
Run by
Amgen
See details and how to joinNCT06570798
Phase 2Taking people
A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
Where
Hollywood, Lawrenceville, Orangeburg
Age
16 years and over
People
30 worldwide
Run by
Akebia Therapeutics
See details and how to joinNCT06419205
Phase 3Taking people
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
Where
Bethesda, Chicago, Cincinnati, Cleveland, Columbus, Durham, El Paso, Greenville, Houston, Los Angeles, New Hyde Park, New Orleans, New York, Philadelphia, Phoenix, Portland, Saint Paul, Salt Lake City, The Bronx, Valhalla, Washington D.C.
Age
5 years to 17 years
People
100 worldwide
Run by
AstraZeneca
See details and how to joinNCT05835310 · EU 2022-502289-25-00
Phase 1Enrolling by invitation
A Study of KITE-363 in Participants With Refractory Autoimmune Diseases
Where
Duarte, New York, Stanford, Tampa
Age
18 years and over
People
52 worldwide
Run by
Kite, A Gilead Company
See details and how to joinNCT07038447
Phase 1/2Taking people
CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
Where
Philadelphia
Age
10 years to 29 years
People
24
Run by
Children's Hospital of Philadelphia
See details and how to joinNCT06839976
Phase 2Taking people
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
Where
Bethesda
Age
18 years to 80 years
People
45
Run by
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
See details and how to joinNCT05440422
No phaseTaking people
Anifrolumab Pregnancy Study
Where
Cary
Age
18 years to 130 years
People
500
Run by
AstraZeneca
See details and how to joinNCT07049653
Phase 2Taking people
Transcutaneous Vagus Nerve Stimulation in SLE
Where
Manhasset
Age
18 years and over
People
18
Run by
Northwell Health
See details and how to joinNCT06987565
Phase 2Taking people
A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
Where
Chicago, Hawthorne, New Hyde Park, Philadelphia
Age
16 years to 70 years
People
20
Run by
iCell Gene Therapeutics
See details and how to joinNCT07328581
Phase 2Taking people
VIBRANT: VIB4920 for Active Lupus Nephritis
Where
Ann Arbor, Atlanta, Aurora, Charleston, Chicago, Hershey, La Jolla, Los Angeles, Manhasset, Miami, New Haven, New York, Orange, Philadelphia, San Francisco, St Louis
Age
18 years and over
People
74
Run by
National Institute of Allergy and Infectious Diseases (NIAID)
See details and how to joinNCT05201469
Phase 4Taking people
Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users
Where
Las Vegas
Age
18 years to 130 years
People
16
Run by
AstraZeneca
See details and how to joinNCT06594068
No phaseTaking people
HEALTH Home Urinalysis Testing
Where
New York
Age
18 years and over
People
160
Run by
NYU Langone Health
See details and how to joinNCT07823478
Phase 2Taking people
The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
Where
Akron, Atlanta, Aurora, Chapel Hill, Charleston, Chicago, Cincinnati, Cleveland, Columbus, Hackensack, Houston, Milwaukee, New York, Salt Lake City, San Francisco, Seattle, St Louis
Age
8 years to 20 years
People
105
Run by
Children's Hospital Medical Center, Cincinnati
See details and how to joinNCT05538208
Phase 2Taking people
A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
Where
Beverly Hills, Cooper City, Dallas, Fayetteville, Fontana, Fullerton, Gainesville, Irvine, Miami, Omaha, San Francisco
Age
12 years to 70 years
People
53
Run by
Fate Therapeutics
See details and how to joinNCT07570862
Phase 3Enrolling by invitation
Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus
Where
Aurora, Baytown, Bellaire, Clearwater, DeBary, Houston, Lake Charles, Las Vegas, Miami, Miami Lakes, San Antonio
Age
18 years to 75 years
People
680 worldwide
Run by
Viatris Innovation GmbH
See details and how to joinNCT06475742 · EU 2024-514354-67-00
Phase 1/2Taking people
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
Where
Atlanta, Baltimore, Bethesda, Boston, Chapel Hill, Charlotte, Chicago, New York, Richmond, San Francisco, Seattle, Stanford, St Louis, Syracuse, Tampa
Age
18 years to 70 years
People
150 worldwide
Run by
AstraZeneca
See details and how to joinNCT06897930